Trendlines Group: Key Corporate and Portfolio Updates – December 2025 & January 2026

Date: 3 February 2026

Location: Misgav, Israel

Key Highlights Investors Should Note

Capital Raising Initiatives

• Proposed and Completed Share Subscriptions:
  • In December 2025, Trendlines announced a proposed subscription for up to 51,447,751 new ordinary shares. The subscription was successfully closed by 29 December 2025.
  • On 7 January 2026, the Group announced a proposed placement for up to 83,680,000 new ordinary shares. The placement was completed by 15 January 2026.
  • These capital raises are significant and inject fresh liquidity into the company. Articles following the placement emphasized the inflow of capital, including from notable investors such as Lion Global, highlighting Trendlines’ strengthened financial position and efforts to drive portfolio windfalls.
  • This is a potentially price-sensitive development as such large capital inflows may influence share value, investor sentiment, and the company’s capacity to fund new investments and growth strategies.

Strategic Partnerships and Management Changes

• Management Transfer Agreement: Trendlines Agrifood Fund Pte Ltd. entered a management transfer agreement with Proterra Investment Advisors (Singapore) Pte. Ltd. in December 2025, with the transaction closing in January 2026. This transition could impact future fund management strategy and performance.
• Executive Appointments:
  • Orit Alaluf Cohen has been appointed as Chief Financial Officer of the Group, a key leadership position that may shape financial strategy and reporting transparency.
  • There was a change in the Corporate Company Secretary and Share Registrar effective from 1 January 2026, reflecting ongoing corporate governance updates.

Corporate Visibility and Investor Relations

• Executive Director and CEO Haim Brosh participated in two major virtual conferences:
  • The Securities Investors Association (Singapore) SIAS Corporate Connect webinar
  • Sidoti’s Year End Virtual Investor Conference

  These events are important for expanding Trendlines’ profile among institutional and retail investors.

Portfolio Company Developments

• Limaca Medical Ltd. announced an exclusive distribution agreement, potentially expanding its market reach and revenue streams.
• PregnanTech Ltd. and Harp Diagnostics Ltd. both opened new funding campaigns, which may drive future growth and innovation in their respective fields.
• Gordian Surgical Ltd. achieved a significant milestone by receiving FDA clearance for its TroClose™ 2.0 product. This regulatory approval is highly price-sensitive as it enables Gordian to access the US market, potentially accelerating revenue and valuation.

Opportunities for Investors

The recent successful capital raisings and strengthened partnerships, coupled with regulatory milestones within the portfolio, position Trendlines for potential growth. The involvement of high-profile investors and the Group’s focus on strategic management updates may enhance confidence in the company’s leadership and corporate governance.

Investors should closely monitor the deployment of new capital, the performance of portfolio companies (particularly those with new distribution agreements and FDA approvals), and further updates regarding fund management transitions.

Stay Updated

For ongoing updates, investors can subscribe to the Trendletter (Trendlines’ monthly newsletter) and sign up for investor alerts covering SGXNet announcements, investor presentations, and financial/corporate information.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information herein is based on public disclosures by Trendlines Group as of 3 February 2026. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The Singapore Exchange Securities Trading Limited (SGX) assumes no responsibility for the contents of this article.

View Trendlines Historical chart here